| 000 | 01829 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513212948.0 | ||
| 264 | 0 | _c20000706 | |
| 008 | 200007s 0 0 eng d | ||
| 022 | _a0361-8609 | ||
| 024 | 7 |
_a10.1002/1096-8652(200007)64:3<156::aid-ajh3>3.0.co;2-f _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPfeilstöcker, M | |
| 245 | 0 | 0 |
_aHematopoietic recovery after IEV chemotherapy for malignant lymphoma followed by different cytokines can be monitored by analysis of Galpha 16 and CD34. _h[electronic resource] |
| 260 |
_bAmerican journal of hematology _cJul 2000 |
||
| 300 |
_a156-60 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntigens, CD34 _xanalysis |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCytokines _xpharmacology |
| 650 | 0 | 4 |
_aEpirubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGTP-Binding Protein alpha Subunits, Gq-G11 |
| 650 | 0 | 4 | _aGene Expression |
| 650 | 0 | 4 |
_aHematopoiesis _xdrug effects |
| 650 | 0 | 4 |
_aHeterotrimeric GTP-Binding Proteins _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIfosfamide _xadministration & dosage |
| 650 | 0 | 4 |
_aLymphoma _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRNA, Messenger _xanalysis |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aKarlic, H | |
| 700 | 1 | _aSalamon, J | |
| 700 | 1 | _aMühlberger, H | |
| 700 | 1 | _aPavlova, B | |
| 700 | 1 | _aStrobl, H | |
| 700 | 1 | _aPittermann, E | |
| 700 | 1 | _aHeinz, R | |
| 773 | 0 |
_tAmerican journal of hematology _gvol. 64 _gno. 3 _gp. 156-60 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/1096-8652(200007)64:3<156::aid-ajh3>3.0.co;2-f _zAvailable from publisher's website |
| 999 |
_c10812734 _d10812734 |
||